نبذة مختصرة : Preterm infants cannot counteract excessive reactive oxygen species (ROS) production due to preterm birth, leading to an excess of lipid peroxidation with malondialdehyde (MDA) production, capable of contributing to brain damage. Melatonin (ME), an endogenous brain hormone, and its metabolites, act as a free radical scavenger against ROS. Unfortunately, preterms have an impaired antioxidant system, resulting in the inability to produce and release ME. This prospective, multicenter, parallel groups, randomized, double-blind, placebo-controlled trial aimed to assess: (i) the endogenous production of ME in very preterm infants (gestational age ≤ 29 + 6 WE, 28 infants in the ME and 26 in the placebo group); (ii) the exogenous hormone availability and its metabolization to the main metabolite, 6-OH-ME after 15 days of ME oral treatment; (iii) difference of MDA plasma concentration, as peroxidation marker, after treatment. Blood was collected before the first administration (T1) and after 15 days of administration (T2). ME and 6-OH-ME were detected by liquid chromatography tandem mass spectrometry, MDA was measured by liquid chromatograph with fluorescence detection. ME and 6-OH-ME were not detectable in the placebo group at any study time-point. ME was absent in the active group at T1. In contrast, after oral administration, ME and 6-OH-ME resulted highly detectable and the difference between concentrations T2 versus T1 was statistically significant, as well as the difference between treated and placebo groups at T2. MDA levels seemed stable during the 15 days of treatment in both groups. Nevertheless, a trend in the percentage of neonates with reduced MDA concentration at T2/T1 was 48.1% in the ME group versus 38.5% in the placebo group. We demonstrated that very preterm infants are not able to produce endogenous detectable plasma levels of ME during their first days of life. Still, following ME oral administration, appreciable amounts of ME and 6-OH-ME were available. The trend of MDA reduction in the active group requires further clinical trials to fix the dosage, the length of ME therapy and to identify more appropriate indexes to demonstrate, at biological and clinical levels, the antioxidant activity and consequent neuroprotectant potential of ME in very preterm newborns.
(© 2023 The Authors. Journal of Pineal Research published by John Wiley & Sons Ltd.)
References: Rees P, Callan C, Chadda KR, et al. Preterm brain injury and neurodevelopmental outcomes: a meta-analysis. Pediatrics. 2022;150:e2022057442.
Kaempf JW, Guillen U, Litt JS, Zupancic JAF, Kirpalani H. Change in neurodevelopmental outcomes for extremely premature infants over time: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2023;108(5):458-463.
Xie Y, Yang Y, Yuan T. Brain damage in the preterm infant: clinical aspects and recent progress in the prevention and treatment. CNS Neurol Disord Drug Targets. 2023;22:27-40.
Volpe JJ. Dysmaturation of premature brain: importance, cellular mechanisms, and potential interventions. Pediatr Neurol. 2019;95:42-66.
Biran V, Phan Duy A, Decobert F, Bednarek N, Alberti C, Baud O. Is melatonin ready to be used in preterm infants as a neuroprotectant? Dev Med Child Neurol. 2014;56:717-723.
Cascant-Vilaplana MM, Sánchez-Illana Á, Piñeiro-Ramos JD, et al. Do levels of lipid peroxidation biomarkers reflect the degree of brain injury in newborns? Antioxid Redox Signal. 2021;35:1467-1475.
Sanchez-Illana A, Pineiro-Ramos JD, Ramos-Garcia V, Ten-Domenech I, Vento M, Kuligowski J. Oxidative stress biomarkers in the preterm infant. Adv Clin Chem. 2021;102:127-189.
Chen HJC, Chen CY, Fang YH, Hung KW, Wu DC. Malondialdehyde-induced post-translational modifications in hemoglobin of smokers by nanoLC-NSI/MS/MS analysis. J Proteome Res. 2022;21:2947-2957.
Colella M, Biran V, Baud O. Melatonin and the newborn brain. Early Hum Dev. 2016;102:1-3.
Saugstad OD. Bronchopulmonary dysplasia-oxidative stress and antioxidants. Semin Neonatol. 2003;8:39-49.
Martini S, Castellini L, Parladori R, Paoletti V, Aceti A, Corvaglia L. Free radicals and neonatal brain injury: from underlying pathophysiology to antioxidant treatment perspectives. Antioxidants (Basel). 2021;10(12):2012.
Matyas M, Hasmasanu MG, Zaharie G. Antioxidant capacity of preterm neonates assessed by hydrogen donor value. Medicina (Kaunas). 2019;55(11):720.
Tordjman S, Chokron S, Delorme R, et al. Melatonin: pharmacology, functions and therapeutic benefits. Curr Neuropharmacol. 2017;15:434-443.
Tan DX, Manchester L, Esteban-Zubero E, Zhou Z, Reiter R. Melatonin as a potent and inducible endogenous antioxidant: synthesis and metabolism. Molecules. 2015;20:18886-18906.
Sánchez-Hidalgo M, Guerrero J, Villegas I, Packham G, de la Lastra C. Melatonin, a natural programmed cell death inducer in cancer. Curr Med Chem. 2012;19:3805-3821.
Tarocco A, Caroccia N, Morciano G, et al. Melatonin as a master regulator of cell death and inflammation: molecular mechanisms and clinical implications for newborn care. Cell Death Dis. 2019;10:317.
Biran V, Decobert F, Bednarek N, et al. Melatonin levels in preterm and term infants and their mothers. Int J Mol Sci. 2019;20(9):2077.
Kennaway DJ, Kennaway DJ, Stamp GE, Goble FC. Development of melatonin production in infants and the impact of prematurity. J Clin Endocrinol Metab. 1992;75:367-369.
Merchant NM, Azzopardi DV, Hawwa AF, et al. Pharmacokinetics of melatonin in preterm infants. Br J Clin Pharmacol. 2013;76:725-733.
Carloni S, Proietti F, Rocchi M, et al. Melatonin pharmacokinetics following oral administration in preterm neonates. Molecules. 2017;22:2115.
Gharehbaghi MM, Yeganedoust S, Shaseb E, Fekri M. Evaluation of melatonin efficacy in prevention of bronchopulmonary dysplasia in preterm newborn infants. Turk J Pediatr. 2022;64:79-84.
Pavlyshyn Н, Sarapuk I, Kozak K. The relationship of melatonin concentration in preterm infants and adverse outcomes in the late neonatal period. Biochem Med. 2023;33:010706.
Cardinali DP. An assessment of melatonin's therapeutic value in the hypoxic-ischemic encephalopathy of the newborn. Front Synaptic Neurosci. 2019;11:34.
D'Angelo G, Cannavò L, Reiter RJ, Gitto E. Melatonin administration from 2000 to 2020 to human newborns with hypoxic-ischemic encephalopathy. Am J Perinatol. 2022;39:824-829.
Ahmed J, Pullattayil S AK, Robertson NJ, More K. Melatonin for neuroprotection in neonatal encephalopathy: a systematic review & meta-analysis of clinical trials. Eur J Paediatr Neurol. 2021;31:38-45.
Garofoli F, Longo S, Pisoni C, et al. Oral melatonin as a new tool for neuroprotection in preterm newborns: study protocol for a randomized controlled trial. Trials. 2021;22:82.
Rizzo V, Porta C, Moroni M, Scoglio E, Moratti R. Determination of free and total (free plus protein-bound) melatonin in plasma and cerebrospinal fluid by high-performance liquid chromatography with fluorescence detection. J Chromatogr B. 2002;774:17-24.
Gitto E, Karbownik M, Reiter RJ, et al. Effects of melatonin treatment in septic newborns. Pediatr Res. 2001;50:756-760.
Di WL, Kadva A, Johnston A, Silman R. Variable bioavailability of oral melatonin. N Engl J Med. 1997;336:1028-1029.
DeMuro RL, Nafziger AN, Blask DE, Menhinick AM, Bertino Jr. JS. The absolute bioavailability of oral melatonin. J Clin Pharmacol. 2000;40:781-784.
Tian X, Huo X, Dong P, et al. Sulfation of melatonin: enzymatic characterization, differences of organs, species and genders, and bioactivity variation. Biochem Pharmacol. 2015;94:282-296.
Marseglia L, Gitto E, Laschi E, et al. Antioxidant effect of melatonin in preterm newborns. Oxid Med Cell Long. 2021;2021:1-8.
Sorensen NL, Maloney SK, Pillow JJ, Mark PJ. Endocrine consequences of circadian rhythm disruption in early life. Curr Opin Endocr Metab Res. 2020;11:65-71.
National Institute of Child Health and Human Development. Drugs and Lactation Database (LactMed®) [Internet], 2006. https://www.ncbi.nlm.nih.gov/books/NBK501863/.
Castellote C, Casillas R, Ramírez-Santana C, et al. Premature delivery influences the immunological composition of colostrum and transitional and mature human milk. J Nutr. 2011;141:1181-1187.
Scheuer T, Endesfelder S, Brinke A, et al. Neonatal oxidative stress impairs cortical synapse formation and GABA homeostasis in parvalbumin-expressing interneurons. Oxid Med Cell Longev. 2022;2022:8469756.
Saugstad OD. Update on oxygen radical disease in neonatology. Curr Opin Obstet Gynecol. 2001;13:147-153.
Balduini W, Weiss MD, Carloni S, et al. Melatonin pharmacokinetics and dose extrapolation after enteral infusion in neonates subjected to hypothermia. J Pineal Res. 2019;66:e12565.
Processing Request
No Comments.